local_hospital

Centro Médico ASISA

Address
Av. Alcalde Manuel de la Pinta, 9, 11008 Cadiz, Spain

Centro Médico ASISA - Respiratory Allergy and Asthma Research Center

Centro Médico ASISA is a specialized clinical research facility dedicated to advancing treatments for respiratory allergic diseases. The center focuses on innovative therapeutic approaches for patients with allergic rhinitis, rhinoconjunctivitis, and allergic asthma, conducting comprehensive studies to improve patient outcomes and quality of life.

  • Allergen-specific immunotherapy research, particularly for dust mite allergies (Dermatophagoides pteronyssinus)
  • Novel asthma medication formulations and delivery systems using advanced propellant technologies
  • Safety and efficacy evaluations of combination therapies for moderate to severe respiratory allergic conditions

The center's research portfolio encompasses both subcutaneous immunotherapy trials investigating optimal dosing strategies for purified allergen combinations and controlled studies evaluating new pressurized metered-dose inhaler (pMDI) formulations. With expertise in GINA-classified asthma management and allergen sensitization protocols, Centro Médico ASISA plays a vital role in developing next-generation treatments for patients suffering from dust mite-induced allergic diseases and chronic respiratory conditions requiring Step 4 and Step 5 therapeutic interventions.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
5
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
0
Sponsors (total)
2
Active sponsors
0

Sponsor Network

Top 10 by active trials.

No sponsors linked to active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
2
Outperforms 47% of sites
public
Therapeutic diversity
2areas
Outperforms 49% of sites
groups
Sponsor diversity
2sponsors
Outperforms 49% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centro Médico ASISA

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Evaluation of Subcutaneous Immunotherapy with Der p 1/Der p 2/Der p 23 Allergens in Moderate/Severe Allergic Rhinitis/Rhinoconjunctivitis with/without Controlled Allergic AsthmaDiater Laboratorio De Diagnostico Y Aplicaciones Terapeuticas S.A.Phase IINot RecruitingApr 2025

IMP list

lock Showing 1 of 5 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Beclometasone Dipropionate Anhydrous1Unknown2024-01-152024-01-15

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.